Baird R W Lowers Catalent (NYSE:CTLT) to Hold

Baird R W downgraded shares of Catalent (NYSE:CTLT) from a strong-buy rating to a hold rating in a research note published on Tuesday, Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Barclays lifted their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research note on Friday, June 28th. Robert W. Baird restated a neutral rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday. William Blair reaffirmed a market perform rating on shares of Catalent in a report on Tuesday, September 3rd. StockNews.com began coverage on Catalent in a report on Wednesday, September 18th. They issued a sell rating for the company. Finally, Royal Bank of Canada reissued a sector perform rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Hold and a consensus price target of $59.83.

Catalent Price Performance

Shares of NYSE CTLT opened at $60.29 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The company’s 50-day moving average price is $59.64 and its 200 day moving average price is $57.31. Catalent has a 52 week low of $31.80 and a 52 week high of $61.20. The stock has a market cap of $10.91 billion, a price-to-earnings ratio of -9.88, a PEG ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.44 by $0.13. The firm had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, research analysts forecast that Catalent will post 0.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Catalent news, insider Ricky Hopson sold 662 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. Lindbrook Capital LLC lifted its holdings in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent during the 2nd quarter valued at about $42,000. Mather Group LLC. bought a new stake in shares of Catalent in the 1st quarter valued at approximately $52,000. Longfellow Investment Management Co. LLC raised its stake in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.